Volume 52, Issue 2 pp. 298-300
Brief Report

Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X

Christopher C. Porter MD

Christopher C. Porter MD

Department of Pediatrics, University of Colorado Denver, Aurora, Colorado

Rick Wilson Center for Cancer and Blood Disorders, The Children's Hospital, Aurora, Colorado

Search for more papers by this author
Amy E. Carver Pharm.D

Amy E. Carver Pharm.D

Rick Wilson Center for Cancer and Blood Disorders, The Children's Hospital, Aurora, Colorado

Search for more papers by this author
Edythe A. Albano MD

Corresponding Author

Edythe A. Albano MD

Department of Pediatrics, University of Colorado Denver, Aurora, Colorado

Rick Wilson Center for Cancer and Blood Disorders, The Children's Hospital, Aurora, Colorado

13123 E. 16th Avenue, B115, Aurora, CO 80045.===Search for more papers by this author
First published: 05 December 2008
Citations: 27

Abstract

Peripheral neuropathy is a well-known side effect of vincristine, a micro-tubule inhibitor commonly used to treat malignancies. Severe neurologic adverse events can occur in patients with Charcot-Marie-Tooth disease (CMT) treated with vincristine. Voriconazole is an antifungal agent used increasingly in children with malignancy. Because of its metabolism by hepatic p450 enzymes, voriconazole may inhibit the clearance of many medications, including vincristine. We report a case of vincristine related neuropathy that was exacerbated by voriconazole in a patient with previously undiagnosed, X-linked CMT. Pediatr Blood Cancer 2009;52:298–300. © 2008 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.